布鲁顿的氨酸激酶抑制抑制了病态视网膜血管生成
Siyue Chen1, Yuming Liu1, Yutian Zhang1
1Department of Ophthalmology, Tianjin Medical University General Hospital, Ministry of Education International Joint Laboratory of Ocular Diseases, Tianjin Key Laboratory of Ocular Trauma, Tianjin Institute of Eye Health and Eye Diseases, China-UK "Belt and Road" Ophthalmology Joint Laboratory, Tianjin, China.
British journal of pharmacology
|October 7, 2024
概括
布鲁顿的氨酸激酶 (BTK) 抑制通过向微质细胞和巨细胞来减少病态视网膜血管生成和血管泄漏. 这种方法为治疗危及视力的眼睛疾病提供了一个有希望的新策略.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
背景情况:
- 病理性视网膜血管生成导致许多眼睛疾病的视力丧失.
- 现有的抗血管内皮生长因子 (VEGF) 治疗通常对一些患者无效.
- 布鲁顿的氨酸激酶 (BTK) 在免疫细胞功能和炎症中起作用.
研究的目的:
- 研究BTK抑制在视网膜血管生成中的抗炎和抗血管原作用.
- 探索BTK抑制剂对眼部疾病的治疗潜力.
主要方法:
- 在C57/BL6J小鼠中氧气诱导视网膜病变模型,通过免疫光检测进行评估.
- 微质枯竭和淋巴细胞缺乏的小鼠用于确定免疫细胞参与.
- 对细胞因子表达,炎症标志物和NLRP3炎症酶激活的分析.
- 与微质细胞和人类视网膜微血管内皮细胞 (HRMEC) 的共同培养实验.
主要成果:
- 抑制BTK显著降低了病态血管生成,血管泄漏和视网膜炎症,主要涉及微质/巨细胞.
- 抑制BTK降低了与NLRP3炎症酶激活相关的促炎细胞因子,并增加了抗炎因素.
- 抑制BTK抑制了微质/巨细胞的炎症活性,与抗VEGF疗法协同作用,并减少了HRMEC的扩散和管形成.
结论:
- 通过调节微质和巨细胞的炎症反应,BTK抑制有效地抑制视网膜新血管化和血管泄漏.
- 阻断BTK是一种新且有前途的治疗策略,用于病态视网膜血管生成.
- 这种方法可以为抗VEGF疗法耐药的患者提供替代或补充治疗.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
01:20The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:10Mechanism of Angiogenesis
5.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K